期刊文献+

艾曲泊帕乙醇胺治疗ITP患者的疗效及其对血小板输注、凝血功能及外周血Th淋巴细胞的影响 被引量:3

Efficacy of eltrombopag in treatment of ITP patients and its effects on platelet transfusion,coagulation function and peripheral blood Th lymphocytes
下载PDF
导出
摘要 目的探讨艾曲泊帕乙醇胺治疗原发免疫性血小板减少症(ITP)患者的疗效及其对血小板输注、凝血功能及外周血Th淋巴细胞的影响。方法选取濮阳市油田总医院103例成人ITP患者,采用随机数字表法分为对照组(51例,给予大剂量地塞米松治疗,并根据血小板数量判定是否输注血小板)和观察组(52例,在对照组基础上联用艾曲泊帕乙醇胺片),观察两组疗效。结果观察组的完全缓解(CR)率、有效(R)率、白介素(IL)-4水平、IL-5水平、血小板计数(PLT)均高于对照组(P<0.05);血小板输注率、血小板输注量、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、IL-2水平、γ干扰素(IFN-γ)水平均低于对照组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论艾曲泊帕乙醇胺可通过调控ITP患者外周血Th淋巴细胞功能,提高PLT,改善凝血功能,减少血小板输注,提高临床疗效,且不易增加用药的不良反应。
作者 程英 郭学军 卫延辉 CHENG Ying;GUO Xuejun;WEI Yanhui
出处 《中国医学工程》 2021年第10期112-114,共3页 China Medical Engineering
  • 相关文献

参考文献6

二级参考文献37

  • 1ProvanD, StasiR, NewlandAC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood,2010,115(2):168-186.
  • 2NeunertC, LimW, CrowtherM, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood,2011,117(16):4190-4207.
  • 3British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol,2003,120(4):574-596. doi:10.1046/j.1365-2141.2003.04131.x.
  • 4WeiY, JiXB, WangYW, et al. High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial[J]. Blood,2016,127(3):296-302. doi:10.1182/blood-2015-07-659656.
  • 5WangS, YangR, ZouP, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J]. Int J Hematol,2012,96(2):222-228. doi:10.1007/s12185-012-1124-8.
  • 6BusselJB, ChengG, SalehMN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura[J]. N Engl J Med,2007,357(22):2237-2247. doi:10.1056/NEJMoa073275.
  • 7BusselJB, ProvanD, ShamsiT, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, doubleblind, placebo-controlled trial[J]. Lancet,2009,373(9664):641-648. doi:10.1016/S0140-6736(09)60402-5.
  • 8ChengG, SalehMN, MarcherC, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study[J]. Lancet,2011,377(9763):393-402. doi:10.1016/S0140-6736(10)60959-2.
  • 9SalehMN, BusselJB, ChengG, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study[J]. Blood,2013,121(3):537-545. doi:10.1182/blood-2012-04-425512.
  • 10KuterDJ, BusselJB, LyonsRM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial[J]. Lancet,2008,371(9610):395-403. doi:10.1016/S0140-6736(08)60203-2.

共引文献464

同被引文献24

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部